Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis
Reviewed by: Alan Gaby, MD
Author: Sahebkar A, et al.
Reference: Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res 2016;105:198-209.
Design: Meta-analysis of 7 randomized controlled trials.
Participants: A total of 409 subjects.
Study Medication and Dosage: Coenzyme Q10 (CoQ10) in dosages of 100-300 mg per day for 4-12 weeks.
Primary Outcome Measure: Plasma lipoprotein(a) levels.
Key Findings: In the pooled analysis, compared with controls, CoQ10 supplementation resulted in a significant decrease in the mean lipoprotein(a) level (weighted mean difference, -3.54 mg/dl; p < 0.001).
Practice Implications: Lipoprotein(a) (Lp[a]) consists of a low-density lipoprotein (LDL) molecule bound by a disulfide linkage to a glycoprotein, apolipoprotein(a). Many, though not all, studies have found that an elevated serum Lp(a) concentration is an independent risk factor for cardiovascular disease.  Although this association does not prove causality, there is evidence that Lp(a) is atherogenic. The results of the meta-analysis suggest that CoQ10 may be useful for cardiovascular disease prevention in people with elevated Lp(a) levels.
 Ariyo AA, et al. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003;349:2108-2115.
 Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997;157:1170-1176.